REFERENCES

1. Furie RA, van Vollenhoven RF, Kalunian K, et al; LILAC Trial Investigators. Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387:894-904.

2. Werth VP, Furie RA, Romero-Diaz J, et al; LILAC Trial Investigators. Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387:321-31.

3. Furie R. Management strategies using biologics in systemic lupus erythematosus. Rare Dis Orphan Drugs J. 2025;4:22.